Passion Flower is well-known historically for its calming properties. The “amount” of calming depends on the dose (see below).

You can take Passion Flower during the day and during the night, with or without food. Try it before business meetings, when anxious, before bed AND during the night if you wake up and your mind is busy.

It helps calm pain, anxiety and can help menstrual cramps too.

More Information

Dr. Iyad Alnahhas interviews Drs. Cynthia Hawkins and Arun Vadivel about their recent manuscript entitled: "The proteomic landscape of diffuse midline glioma highlights the therapeutic potential of non-histone protein methyltransferases", published online in Neuro-Oncology in February 2025.

More Information

Dr. Iyad Alnahhas interviews Dr. Peter LaViolette about his and his team's recent manuscript entitled: "Multi-Site Retrospective Analysis of Diffusion and Perfusion MRI Correlates to Glioma Characteristics Derived from Radio-Pathomic Maps", published online in Neuro-Oncology in February 2025.

Dr. Iyad Alnahhas interviews Dr. Craig Horbinski about his and his team's recent manuscript entitled "The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma", published online in Neuro-Oncology in December 2024.

Dr. Iyad Alnahhas interviews Dr. Nathalie Albert about her and her team's recent manuscript entitled: "Measurable disease as baseline criterion for response in glioblastoma: A comparison of PET-based (PET RANO 1.0) and MRI-based (RANO) assessments", published online in Neuro-Oncology in January 2025.

Dr. Iyad Alnahhas interviews Dr. Danielle Bazer about her and her team's recently published manuscript, entitled: Using a Pre-Radiation Window to Identify Potentially Active Cytotoxic Agents in Adults with Newly Diagnosed Glioblastoma", published online in Neuro-Oncology in November 2024.

Dr. Iyad Alnahhas interviews Drs. Thomas Zeyen and Johannes Weller about their recent manuscript entitled: "Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with CCNU/TMZ", published online in Neuro-Oncology in October 2024.